These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9680102)

  • 1. A pilot trial of 13-cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias. The Central Pennsylvania Oncology Group.
    Besa EC; Kunselman S; Nowell PC
    Leuk Res; 1998 Aug; 22(8):741-9. PubMed ID: 9680102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol.
    Besa EC; Abrahm JL; Bartholomew MJ; Hyzinski M; Nowell PC
    Am J Med; 1990 Dec; 89(6):739-47. PubMed ID: 2252043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.
    Tatarelli C; Piccioni AL; Maurillo L; Naso V; Battistini R; D'Andrea M; Criscuolo M; Nobile C; Villivà N; Mancini S; Neri B; Breccia M; Fenu S; Buccisano F; Voso MT; Latagliata R; Aloe Spiriti MA
    Ann Hematol; 2014 Aug; 93(8):1413-20. PubMed ID: 24647684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial.
    Cazzola M; Ponchio L; Beguin Y; Rosti V; Bergamaschi G; Liberato NL; Fregoni V; Nalli G; Barosi G; Ascari E
    Blood; 1992 Jan; 79(1):29-37. PubMed ID: 1728318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.
    Case DC; Bukowski RM; Carey RW; Fishkin EH; Henry DH; Jacobson RJ; Jones SE; Keller AM; Kugler JW; Nichols CR
    J Natl Cancer Inst; 1993 May; 85(10):801-6. PubMed ID: 8487324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
    Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
    Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile?
    Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
    Leuk Lymphoma; 1993 Jan; 9(1-2):79-83. PubMed ID: 8477205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children.
    Varan A; Büyükpamukçu M; Kutluk T; Akyüz C
    Pediatrics; 1999 Feb; 103(2):E16. PubMed ID: 9925862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.
    Giraldo P; Nomdedeu B; Loscertales J; Requena C; de Paz R; Tormo M; Navarro P; Benedit P; Gasquet JA;
    Cancer; 2006 Dec; 107(12):2807-16. PubMed ID: 17115424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
    Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
    Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report.
    Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
    Haematologica; 1993; 78(2):123-6. PubMed ID: 8349188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia.
    van Kamp H; Prinsze-Postema TC; Kluin PM; den Ottolander GJ; Beverstock GC; Willemze R; Fibbe WE
    Br J Haematol; 1991 Aug; 78(4):488-93. PubMed ID: 1911340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival.
    Crisà E; Foli C; Passera R; Darbesio A; Garvey KB; Boccadoro M; Ferrero D
    Br J Haematol; 2012 Jul; 158(1):99-107. PubMed ID: 22571649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of recombinant human erythropoietin (rhuEPO) in treatment of anemia in patients with myelodysplastic syndrome].
    Wiecek A; Chudek J; Nieszporek T; Kokot F
    Pol Arch Med Wewn; 1992 Dec; 88(6):451-7. PubMed ID: 1300567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia.
    Mittelman M; Zeidman A; Fradin Z; Magazanik A; Lewinski UH; Cohen A
    Acta Haematol; 1997; 98(4):204-10. PubMed ID: 9401498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.